Inflammatory Bowel Disease | Marketed Drugs update.
'Biosimilars threaten blockbuster biologics'
By Joseph Hedden, Senior Analyst
21 August 2013
I am an analyst at Datamonitor Healthcare, having previously completed a PhD in Structural and Molecular Biology at Univ...
Read full bio
The expiry of Remicade’s (infliximab) EU patent in 2015 will mark the start of a decline in sales for all branded biologic therapies for Crohn’s disease and ulcerative colitis.
Datamonitor Healthcare expects infliximab biosimilars to launch from 2015, and that physicians will gradually switch to prescribing these cheaper drugs rather than branded Remicade. As no other drug is more effective, biosimilar infliximab is also likely to take market share from other key brands, including Humira, Simponi, Cimzia, and Tysabri.
In-depth analysis of key brands for inflammatory bowel disease, including a review of clinical data and a comparative evaluation of clinical and commercial drug attributes to determine competitiveness in the marketplace.
- The anticipated arrival of biosimilars from 2015 threatens the future commercial success of blockbuster biologics Remicade and Humira.
- Increasing generic competition will continue to erode market shares of branded mesalamine-based drugs.
- Lialda is the most clinically attractive drug for the treatment of ulcerative colitis, but ongoing patent challenges threaten its commercial success.
- The commercial potential of biologics Cimzia and Tysabri is reduced by limited patient populations stemming from marketing rejections in the EU.
This is an Immunology and Inflammation analysis update from the Datamonitor Healthcare service, which provides regular and event-senstive research for key drugs and companies, treatment trends, patient populations and strategic issues.
- For more information on this research, please contact
- For current clients, please log-in to view the full analysis at: